ArticlePain and therapy2021
ED50 of Propofol Combined with Nalbuphine on the Sedative Effect in Painless Hysteroscopy.
Article in Pain and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Comparison of intravenous nalbuphine and sufentanil on the median effective effect-site concentration of propofol to attenuate the response to cervical dilation during hysteroscopy: a double-blind, dose-response study.BMC anesthesiology · 2025Trial
- The median effective dose (EDBMC anesthesiology · 2026Article
- Opioid receptor agonist-antagonists in pain management: receptor specific mechanisms, dose response relationships, and clinical combination strategies.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Effective Doses of Oliceridine Combined with Propofol for Painless Hysteroscopy: A Prospective Dose-Finding Study.International journal of general medicine · 2025Article
- Clinical study on the safety and efficacy of remimazolam in hysteroscopic surgery under general anesthesia in elderly patients.Frontiers in medicine · 2024Article
- The median effective dose of propofol combined with butorphanol during artificial abortion: a randomized controlled trial.Frontiers in medicine · 2023Article
- Modified Dixon sequential method to determine the effective dose of alfentanil compounded with propofol for day-case hysteroscopy.Therapeutic advances in drug safety · 2023Article
- Analgesic Effects and Safety of Dexmedetomidine Added to Nalbuphine or Sufentanil Patient-Controlled Intravenous Analgesia for Children After Tonsillectomy Adenoidectomy.Frontiers in pharmacology · 2022Article
- The median effective doses of propofol combined with two different doses of nalbuphine for adult patients during painless gastroscopy.Frontiers in pharmacology · 2022Article
- Effective Doses of Nalbuphine Combined with Propofol in Painless Hysteroscopy.International journal of general medicine · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
introductionNalbuphine has gradually become a commonly used clinical analgesic drug for painless hysteroscopy. The aim of our study was to identify the median effective dose (ED50) of propofol combined with nalbuphine for painless hysteroscopy.
methodsSixty-one patients aged 18-60 years were recruited to undergo elective painless hysteroscopy. Patients were administered 0.1 μg/kg nalbuphine (group A) or 0.2 μg/kg nalbuphine (group B) intravenously 3 min before endoscopic placement. The Dixon sequential method was used with an initial intravenous propofol dose of 2 mg/kg, which varied by 0.5 mg per kilogram.
resultsThe ED50 of propofol was 1.729 mg/kg (95% confidence interval [CI] 1.526-1.856 mg/kg) in group A and 1.658 mg/kg (95% CI 1.359-1.799 mg/kg) in group B. The 95% effective dose (ED95) of propofol was 2.051 mg/kg (95% CI 1.899-3.331 mg/kg) in group A and 2.020 mg/kg (95% CI 1.849-3.832 mg/kg) in group B.
conclusionFor safety and effective painless hysteroscopic, the ED50 values of propofol combined with nalbuphine were 1.729 mg/kg (0.1 mg/kg nalbuphine) and 1.658 mg/kg (0.2 mg/kg nalbuphine). The recommended dose of nalbuphine is therefore 0.1 mg/kg.
trial registrationChinese Clinical Trial Registry: ChiCTR2100042342 ( http://www.chictr.org.cn/edit.aspx?pid=66342&htm=4 ; registration date 19 Jan 2021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.